This article reviews preclinical gene replacement strategies for the treatment of hereditary hearing loss, touches on the criteria of a good therapeutic target, and outlines qualities of CABP2 that make it an excellent therapeutic target. The gene discussed is CABP2; the disease is hearing loss disorder.